/
MacroGenics , the MacroGenics logo, DART , TRIDENT and the phrases Breakthrough Biologics, Life-Changing Medicines and Developing Breakthrough Biologics, Life-Changing Medicines are our trademarks. The other trademarks, trade names and service marks appearing in this report are the property of their respective owners.
The business is unprofitable at the operating level (-48.72% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 0.3% YoY. The question is whether this is cyclical or a structural shift.
Negative free cash flow of -$83M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$157M
▼ -0.3% YoY
Net Income (TTM)
-$70M
▼ -11.4% YoY
Op. Margin
-40.52%
▲ +25.0pp YoY
ROIC
-59.52%
▲ +4.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$72M
▼ -15.1% YoY
Op. Cash Flow (TTM)
-$70M
▼ -18.5% YoY
Net Debt
-$30M
Net Cash Position
Cash & Equiv.
$67M
5Y CAGR: +7.3%
Continue Research